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Abstract
Introduction: Terminal ileum resection in patients with
Crohn’s disease results in vitamin B12 deficiency and these
patients are routinely given B12 supplementation to
prevent anemia and neuropsychiatric disease. The effect
of right hemicolectomy on B12 status in cancer patients
has not previously been studied. Total serum B12 is an
unreliable test. Second-line diagnostic tests measure
methylmalonic acid (MMA) and homocysteine (tHcy) are
also used. An assay measuring an active form of B12 is
available for routine use. This observational study
investigated whether B12 deficiency exists in patients after
a right hemicolectomy for cancer.
Methods: Patients (n=28; age range=52-88 years) who
had undergone a right hemicolectomy for cancer and
been in remission for two years were identified from a
database and recruited to an outpatient clinic along with
an age-matched control group (n=27; age range=52-89
years). Vitamin B12 status in both patients and controls
was assessed by the measurement of vitamin B12 (total
and active), MMA and tHcy.
Results: Concentration of tHcy was significantly higher
(p<0.05) in the surgical group (14.0 µmol/L) compared
with the controls (11.1 µmol/L). There were no significant
differences in total and active B12, folate and MMA
concentrations between the two groups (p>0.05).
Discussion: Right hemicolectomy for malignancy is
associated with an increase in tHcy concentrations
although a larger study is required to determine the B12
status in post-operative right hemicolectomy patients.
Keywords: Right hemicolectomy; Vitamin B12 deficiency;
MMA; tHcy; Cancer; Crohn’s disease
Introduction
Cancer Research UK reports bowel cancer as the fourth
most common cancer for both men and women in the UK,
with 41,112 bowel cancer cases in the UK, and 2,272 in Wales
in 2013 [1]. Sixty- three per cent of bowel cancer patients had
surgical intervention in 2015 [2] with some undergoing a right
hemicolectomy with various degrees of the terminal ileum
being resected.
There has been no study to investigate vitamin B12
deficiency in people undergoing right hemicolectomy for
malignancy however those who have had the same procedure
for Crohn’s disease are prescribed B12 supplementation
because of recognised deficiencies. Crohn’s ileal resections of
less than 20 cm in length have variable consequences on B12
status [3] although patients who have had more than 20 cm of
terminal ileum excised almost invariably have vitamin B12
deficiency [4].
Vitamin B12 plays a key role in DNA and cell metabolism and
long term deficiency can cause severe and irreversible
damage. Effects of B12 deficiency include fatigue, bone
marrow suppression, neurological features including stroke,
and risk of cardiomyopathy [5-8]. It has been recognised that
B12 deficiency can cause symptoms of psychosis, mania,
memory impairment, fatigue, irritation and personality
changes. Deficiency can be treated with vitamin B12
supplementation, which if given for life has the potential to
improve well-being and longevity.
Vitamin B12 (cobalamin) is bound to two proteins;
transcobalamin (TC) and haptocorrin (HC). The
transcobalamin-vitamin B12 complex, also known as
holotranscobalamin (HoloTC), contains the biologically
available B12 HoloTC mediates the uptake of B12 by all cells
utilising specific receptors whereas 80% of B12 which is bound
to HC is metabolically inert [8,9]. Measurement of total B12
(cobalamin) in serum by immunoassay is the most widely
available test for assessing B12 status. However, this test
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measures both the active and inactive forms and has a low
sensitivity. Currently methylmalonic acid (MMA) and
homocysteine (tHcy) are recommended as second line tests if
total B12 results are in the indeterminate range, as they are
considered to be more sensitive tests although tHcy is less
specific. Both MMA and tHcy depend on B12 as a cofactor for
their metabolism. An increase in MMA or total tHcy in folate
replete individuals indicates B12 deficiency in tissue [7,10]. The
metabolically active B12 can now be measured by an
immunoassay and recent evidence suggests that this is a more
reliable marker of impaired vitamin B12 status than total B12
[7,10]. However, it also recommended that MMA is used as a
confirmatory test if the result is in the indeterminate range.
In this present study, we measure both total and active B12,
tHcy and MMA in addition to other variables to determine B12
status in patients who have undergone right hemicolectomies
for cancer and in age-matched controls (controls).
Materials and Methods
Recruitment of participants
Adults treated with a right hemicolectomy for
gastrointestinal cancer at Nevill Hall Hospital who had been in
remission for two years or more were identified from an
internal database and invited to join the study. Potential
participants were excluded with the following conditions:
already receiving vitamin B12 supplementation, pregnant,
anemic or unable to give written consent. The study gained
ethical approval from the NHS South Central Hampshire B
Research ethics committee (REC No 15/SC/0756 PR). All
participants gave written informed consent. Twenty-eight
participants attended a clinic where blood samples were taken
along with twenty-seven age-matched controls (Table 1).
Table 1 Descriptive characteristics for all participants (n=55) and for controls (n=27) and patient (n=28) subgroups. 
Total cohort Controls Patients P
n (%) 55 (100%) 27 (49%) 28 (51%)
75 (52-89) 77 (52-89) 74 (52-88) 0.933
40:15 22:5 18:10 -
317 (125-895)d 324 (195-895)b 295 (125-652)b 0.243
65.3 (23.4-257.0)a 69.3 (23.4-257.0) 63.7 (27.5-170.1)a 0.782
5.8 (1.5-20.0)d 5.8 (1.5-20.0)b 5.7 (2.3-16.0)b 0.902
0.29 (0.16-2.80) 0.28 (0.21-0.81) 0.33 (0.16-2.80) 0.619
12.6 (6.5-38.0) 11.1 (6.9-34.5) 14 (6.5-38.0) 0.037
136 ± 19a 133 ± (24)a 139 ± (15) 0.256
Age (years)
Gender (M:F)
Total B12 (ng/L) 
Active B12 (pmol/L) 
Folate (µg/L)
MMA (µmol/L) 
Homocysteine (µmol/L) 
Haemoglobin (g/L) 
MCV (fL) 89.0 (79-112)a 89 (80-112)a 90 (79-104) 0.549
82 (59-148)c 77 (61-119)b 84 (59-148)a 0.223
eGFR (mL/min/1.73 m2) (mean ± SD) 73 ± 17c 78 ± 15b 68 ± 17a 0.040
TI Excised (cms) - - 80 (60-400) -
Days post resection 1747 (770-2812)a
Laboratory analyses
Blood samples were collected, transported to the laboratory
within 30 minutes and analysed on the same day with the
exception of plasma tHcy, plasma MMA, and active vitamin
B12, where samples were stored at -80°C for up to one month
prior to analysis. For plasma tHcy, samples were separated and
frozen within 30 minutes of venepuncture.
Serum total B12, folate, creatinine and tHcy, were analysed
on the Abbott ARCHITECT ci8200 analyser (Abbott Diagnostics,
Berkshire, UK). Full blood count parameters including
haemoglobin and mean cell volume (MCV) were performed by
a SYSMEX XE-2100 analyser (SYSMEX, Kobe, Japan). Plasma
concentrations of MMA were determined by GC-MS. Serum
active B12 was analysed by an Abbott chemiluminescent
microparticle immunoassay (CMIA) on the Abbott ARCHITECT
ci8200 analyser. Within-batch coefficients of variation (CVs)
were 4.1% and 5.3% at concentrations of 15.8 pmol/L and 46.8
pmol/L, respectively. Between-batch CVs were 7.6% and 5.7%
at concentrations of 15.8 pmol/L and 46.8 pmol/L,
respectively. Glomerular filtration rate was estimated using a
four-variable MDRD equation. For the purpose of this study,
renal disease was defined as estimated GFR (eGFR) <60
mL/min/1.73 m2 [11]. Local reference ranges were used for all
analytes with the exception of the reference range for active
B12 [12].
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Note: continuous variables are expressed as median (range) unless stated otherwise. tHcy, homocysteine; MMA, methylmalonic acid; eGFR, estimated glomerular 
filtration rate; MCV, mean cell volume. Missing number of samples are shown, a: n-1, b:  n- 2, c: n-3, and d: n-4. 
Creatinine (µmol/L)
Statistical Analysis
Data were analysed using statistical software (Analyse-It,
Leeds UK and Sigmaplot V13 Systat Ltd, UK). Most of the data
were not normally distributed and were expressed as median
(range) unless stated otherwise. Non-parametric Mann-
Whitney U-test was used for comparison between patients
and controls. For normally distributed data the unpaired T-test
was used. Spearman rank analysis was used to test for
univariate relationships between markers of vitamin B12 status
with clinical variables. A p value of <0.05 was considered
statistically significant. Agreement between different markers
of B12 status was undertaken using the weighted kappa test for
agreement: kappa statistic (κ) <0.2 was considered a poor
strength of agreement.
Results
Eleven of 26 (42%) patients and 10 of 26 (38%) controls had
total B12 concentrations within the indeterminate range
(180-300 ng/L) (Table 1). In comparison, a slightly higher
proportion of patients (56% (15 of 27)) and controls (48% (13
of 27)) had active B12 concentrations in the indeterminate
range (25-70 pmol/L). However, 3 of 26 (12%) patients
demonstrated total B12 deficiency (<180 ng/L) compared with
none in the control group. Conversely, active B12 results
revealed that 1 of 27 controls (4%) was deficient (<25 pmol/L)
compared with none in the patient group. Taken together,
there was a high proportion of patients who were not replete
in B12; 56% and 53% for active B12 total B12, respectively. A
slightly lower proportion of controls were not replete in B12;
50% for active B12 and 40% for total B12.
Of those study participants (patients and controls) who
were not replete in active B12 (<70 pmol/L), only 9 of 30 (30%)
and 8 of 30 (27%) had raised MMA (>0.42 µmol/L) and tHcy
(>16.0 µmol/L) concentrations, respectively. Study participants
who were not replete in total B12 (<300 ngl/mL), 4 of 24 (17%)
and 5 of 24 (21%) had raised MMA (>0.42 μmol/L) and tHcy
(>16.0 µmol/L) concentrations, respectively. Thus, agreement
between total B12 and MMA (κ=0.02), active B12 and MMA
(κ=0.07), tHcy and total B12 and tHcy (k=0.01), active B12 and
tHcy (κ = 0.02) for the diagnosis of B12 deficiency was poor in
this population. Of those with deficient total B12 results (<180
ng/L; n=3 patients), active B12 results were all in the
indeterminate range or above, one MMA and two tHcy results
were elevated, and one tHcy result was at the upper end of
the reference range. In contrast, only one control had a
deficient active B12 result (<25 pmol/L). However total B12 was
in the indeterminate range and MMA and tHcy concentrations
were both normal.
Plasma homocysteine concentration (14.0 µmol/L) was
significantly higher in patients compared with controls (11.1
µmol/L) (p=0.037). Ten of 28 (36%) patients exhibited an
elevated tHcy concentration (>16.0 µmol/L) compared with 4
of 27 (15%) of controls. eGFR was significantly lower in
patients (68 mL/min/1.73 m2) compared with controls (78
mL/min/1.73 m2) (p=0.04). However, only seven of the
patients and four of the controls had eGFR <60 mL/min/1.73
m2. There were no significant differences (p>0.05) in total or
active B12, MMA, haemoglobin (Hb) and mean cell volume
(MCV) between the two groups. The prevalence for abnormal
MMA (>0.42 µmol/L) in patients and controls was 21% (6 of
28) and 19% (5 of 27), respectively.
Univariate analyses for the patient subgroup (Table 2)
revealed that tHcy correlated negatively with folate and eGFR
and positively with MMA. However, in the controls, tHcy only
correlated negatively with folate (Table 3). In patients, total
B12 only correlated positively with active B12 compared with
total B12 in control participants which correlated positively
with active B12, folate and MCV. In patients, active B12
correlated positively with total B12 and negatively with MMA,
and Hb. In the controls active B12 correlated negatively with
folate and positively with total B12. Due to the small study
numbers, the independent effect of variables on B12 status
was not analyzed.
Table 2 Correlation between vitamin B12 status markers and clinical variables in patients (n=28). 
tHcy Total B12 Active B12 MMA
rs p rs P rs P rs P
tHcy - - -0.27 0.19 -0.25 0.20 0.43 0.022
Total B12 -0.27 0.19 - - 0.49 0.01 -0.16 0.42
Active B12 -0.25 0.20 0.49 0.01 - - -0.55 0.003
MMA 0.43 0.02 -0.16 0.42 -0.55 0.003 - -
Folate -0.74 <0.0001 0.02 0.90 0.24 0.24 -0.45 0.02
Hb -0.06 0.76 -0.32 0.11 -0.44 0.02 0.32 0.10
eGFR -0.52 0.005 -0.25 0.22 -0.07 0.72 -0.12 0.53
MCV 0.19 0.34 0.19 0.34 0.14 0.48 0.04 0.82
TI 0.17 0.38 -0.20 0.33 -0.04 0.83 0.02 0.93
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Note: rs, correlation coefficient,; tHcy, homocysteine; MMA, methylmalonic acid; Hb, haemoglobin; eGFR, estimated glomerular filtration rate; MCV, mean cell volume; TI, 
terminal ileum length; Resection, days post resection. 3
Resection 0.06 0.75 0.10 0.64 0.10 0.61 -0.12 0.54
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Table 3 Correlation between vitamin B12 status markers and clinical variables in control group (n=27).
tHcy Total B12 Active B12 MMA
rs P rs p rs p rs P
tHcy - -0.26 0.20 -0.32 0.10 0.27 0.18
Total B12 -0.26 0.20 - - 0.51 0.01 0.24 0.25
Active B12 -0.32 0.10 0.51 0.01 - - -0.13 0.52
MMA 0.27 0.18 0.24 0.25 -0.13 0.52 - -
Folate -0.62 0.001 0.43 0.03 0.44 0.03 0.12 0.57
Hb 0.19 0.34 0.05 0.98 -0.00 0.99 -0.03 0.89
eGFR -0.36 0.08 0.35 0.10 0.34 0.10 -0.08 0.69
MCV -0.20 0.32 0.46 0.02 0.36 0.07 0.07 0.74
Discussion
This is the first study to assess B12 status in patients who
have undergone a right hemicolectomy for cancer. The study
has demonstrated that tHcy concentrations were mildly
elevated in patients compared with controls. Over twice as
many patients had abnormal tHcy concentrations (>16.0
µmol/L) compared with controls. While vitamin B12 deficiency
results in an elevated plasma tHcy, and is a sensitive marker of
vitamin B12 deficiency, it is not specific to vitamin B12
deficiency and is a nonspecific marker for many diseases
including cardiovascular diseases and dementia [13-15].
Recent studies suggest that mildly elevated concentrations of
tHcy may be an indicator of atherosclerosis and cardiovascular
disease [14]. However, mildly elevated concentrations (<50
µmol/L) frequently occur in the general population and are
influenced by many factors, including folate deficiency, vitamin
B6 deficiency poor renal function, hypothyroidism, lifestyle
factors (smoking, alcoholism, diet) age and gender, drug
therapy and certain genetic polymorphisms. The main
predictors of elevated plasma tHcy concentrations are low
folate, vitamin B12 status or renal impairment [13,14].
Although an inverse relationship exists between tHcy and
folate in both patients and controls in this study, all
participants, apart from one patient and one control, were
defined as folate replete (>2.4 µg/L). Similarly, this study
demonstrated an inverse relationship between tHcy and eGFR.
Hyperhomocysteinaemia (<50 µmol/L) is known to occur when
eGFR falls below 60 mL/min/1.73 m2 [16]. Furthermore, it has
been demonstrated that renal impairment causes an increase
in tHcy and MMA concentrations in an aged population (≥ 65
years) [17]. In the present study, six of the ten patients with
raised tHcy concentrations exhibited concurrent impaired
renal function (eGFR <60 mL/min/1.73 m2) whereas four
patients had normal renal function (eGFR >60 mL/min/1.73
m2). However, the assessment of renal function (eGFR <60 mL/
min/ 1.73 m2) in this study is based on a single measurement
and it is recommended that diagnosis of chronic kidney
disease is recorded over at least three months [18]. On repeat
testing some participants with eGFR <60 mL/min/1.73 m2 may
exhibit a higher eGFR and vice versa. Notably, the median age
of our population is 77 years and thus an effect on renal
function is likely which may in turn compromise the
interpretation of tHcy and MMA results. The independent
effect of renal function on the measurement of tHcy and MMA
was not investigated.
The thyroid function and vitamin B6 status of this group
were not investigated and cannot be ruled out as causes. It is
possible that these patients also have cardiovascular disease
but details of this co-morbidity were not recorded at
recruitment and was not part of the exclusion criteria. Further
work is necessary to establish the cause of mildly elevated
tHcy in this patient group.
Although the study did not show significant differences in
active B12 concentrations between patients and controls there
was an inverse relationship between active B12 and MMA
within the patient cohort which was not observed amongst
controls. Due to the small numbers of participants in this
study, the independent effect of variables on MMA and B12
concentrations was not explored.
This study highlights the difficulty in defining B12 status
using various circulating markers. The total B12 and active B12
results both demonstrate that a large proportion of patients
and controls fall within the indeterminate range. According to
recent British Journal of Haematology guidelines, patients with
a reduced total B12 and normal tHcy and MMA do not require
any further investigations and are not classified as B12
deficient [19]. In the current study, further testing using the
recommended second-line investigations, MMA or tHcy,
revealed that only a quarter of the study participants with
indeterminate active B12 results and only a fifth with
indeterminate total B12 results, may be B12 deficient. Although
many studies recommend these second line investigations
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Note: rs, correlation coefficient; tHcy, homocysteine; MMA, methylmalonic acid; Hb, haemoglobin; eGFR, estimated glomerular filtration rate; MCV, mean cell volume.
there is currently not a gold standard test available for B12
status. Recently, active B12 has been shown to be the best
marker of B12 status in older people (n=700; mean age=81
years) when compared with red cell cobalamin [7].
Furthermore, in this study the indeterminate range was
defined as 20-30 pmol/L and anything above that was defined
as normal. If these cut-offs are applied to these data then all
study participants would be defined as replete despite having
elevated MMA and tHcy concentrations, thereby highlighting
the importance of establishing local reference ranges due to
variations between populations and methodologies. For the
present study, the reference ranges for active B12
recommended by the referral laboratory in London have been
used, which may not represent the population in South Wales.
It would be useful to establish a local reference range for
active B12. Thus, further work is necessary before the B12
status can be accurately determined in our local population
and also in cancer patients who have undergone right
hemicolectomy.
Of the participants classified as B12 deficient (determined by
either total or active B12) none were found to have
macrocytosis and/or anemia. Similarly, a Finnish study
investigating the prevalence of B12 deficiency in an elderly
population (n=1048; age range: 65-100 years) demonstrated
that anemia or macrocytosis did not predict B12 deficiency and
only two of their 97 subjects with B12 deficiency would have
been diagnosed based on these observations [20]. This raises
the question of the sensitivity of this approach in the early
diagnosis of B12 deficiency.
The small sample size in this study does not allow a detailed
analysis of B12 status as originally anticipated. These results
demonstrate that a high proportion of patients (54%) and
controls (48%) are not replete in vitamin B12. Whether this is a
true representation of the local population needs further
investigation and a further larger study would allow a better
stratification of study participants into those who are vitamin
B12 deficient or replete. The population (600,000) served by
Aneurin Bevan University Health Board come from both rural
and suburban areas, with a mix of socioeconomic status.
Those living in rural and lower socioeconomic areas may have
a limited access to healthcare and as a consequence are more
likely to be vitamin B12 deficient.
In conclusion, this study demonstrates that there are subtle
differences between the controls and patients who have
undergone a right hemicolectomy for cancer. We recommend
that vitamin B12 status is investigated further using the
aforementioned recommended laboratory markers for tissue
vitamin B12 stores in order to understand how terminal ileum
excision alters this essential regulatory system. Replenishing
vitamin B12 may improve short and long-term outcomes of
patients that have had a right hemicolectomy.
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